Argenx Archives

News and Trends 14 Jul 2022

Agomab bags $114 million in thriving regenerative medicine sector

The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million to hit $114 million. This Pfizer-led financing round extension is just the latest sign that the emerging field of regenerative medicine is coming to the fore. Agomab has embarked on an ambitious path to redefine how we understand regenerative medicine […]

July 14, 2022 - 3 minutesmins - By Victor Kotsev

argenx efgartigimod treatment autoimmune disease myasthenia gravis

News and Trends 21 Dec 2021

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle disease generalized myasthenia gravis, opening up its developer argenx to billion-dollar revenues. Efgartigimod, to be marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval […]

December 21, 2021 - 4 minutesmins - By Anita Chakraverty

Best in Biotech 20 Dec 2021

The Billion-Euro European Biotech Companies in 2022

Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […]

December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin

biotech stock price euronext genmab argenx

News and Trends 25 May 2021

Delayed IPOs and Market Drops Batter Biotech Stocks

Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […]

May 25, 2021 - 6 minutesmins - By Jonathan Smith

Best in Biotech 11 Jan 2021

The 21 European Biotech Companies To Watch in 2021

As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]

January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 29 May 2020

Argenx Follows up Phase III Success with Giant €785M Global Offering

The Dutch biotech argenx has cashed in on recent positive phase III results by launching an enormous €784.7M ($862.5M) global share offering. Argenx’s fundraise swiftly follows the announcement of phase III trial results earlier this week, where its lead candidate antibody drug, efgartigimod, improved motor symptoms of patients with the chronic autoimmune disease myasthenia gravis. […]

May 29, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 26 May 2020

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved motor symptoms of the autoimmune disease myasthenia gravis in a phase III trial. The phase III trial tested the effect of efgartigimod in 167 patients with generalized myasthenia gravis. In this incurable chronic condition, the […]

May 26, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Nov 2019

Argenx Raises Whopping €502M in Global Offering

The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has raised an eye-watering €502M ($557M) in a global offering on the Nasdaq Stock Exchange and Euronext Brussels. Argenx’s global offering was launched last week. It consists of a private placement in Europe as well as a public offering in the […]

November 11, 2019 - 2 minutesmins - By Jonathan Smith

More News! 3 Apr 2019

€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies

The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could regenerate damaged tissue. The round was led by the Belgian investor V-Bio Ventures and Advent France Biotechnology. AgomAb will use the big Series A funding to test antibody treatments for fibrosis in clinical trials, as […]

April 3, 2019 - 2 minutesmins - By Jonathan Smith

argenx llama inspired antibodies cover cancer immunotherapy

News and Trends 5 Dec 2018

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen into a collaboration to advance their use in cancer immunotherapy. In a phase II trial, the company’s lead antibody, efgartigimod, reduced the number of bleeding […]

December 5, 2018 - 3 minutesmins - By Jonathan Smith

More News! 19 Sep 2018

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after announcing positive Phase II results for its lead autoimmune drug candidate. The company now plans to progress efgartigimod, an antibody fragment inspired by llama antibodies, to Phase III trials for treatment of the autoimmune blood disease primary immune thrombocytopenia (ITP). […]

September 19, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 14 Dec 2017

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Today, the Belgian biotech has announced that it has raised a very impressive $231M (€195M) following positive results at ASH. The company […]

December 14, 2017 - 1 minutemin - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Argenx

Agomab bags $114 million in thriving regenerative medicine sector

Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease

The Billion-Euro European Biotech Companies in 2022

Delayed IPOs and Market Drops Batter Biotech Stocks

The 21 European Biotech Companies To Watch in 2021

Argenx Follows up Phase III Success with Giant €785M Global Offering

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

Argenx Raises Whopping €502M in Global Offering

€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies

Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal

Argenx Attracts Huge €250M Investment Following Positive Phase II Trial

Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!